NBIX
NEUROCRINE BIOSCIENCES INCCompany Information
- Company Name
- NEUROCRINE BIOSCIENCES INC
- CIK
- CIK0000914475
- Category
- Large accelerated filer
- Ticker: Exchange
- NBIX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- NBIX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-29
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 648,230
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 91,721,782
- Shares outstanding
- 100,500,000
- Ownership
- 91.27%
Earnings Market Reaction
- Filing date
- 2026-07-31
- Price on filing date
- —
- 1-month reaction
- Pending
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 332 | 267 | 713 | 340 | 264 | 194 | 233 | 349 | 140 | 396 | 251 | 294 | ||||||
| Available For Sale Securities Debt Securities Current | 57 | 1,050 | 767 | 775 | 712 | 749 | 843 | 879 | 899 | 814 | 781 | 801 | ||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | - | - | 439 | - | ||||||
| Accounts Receivable Net Current | 887 | 768 | 687 | 728 | 596 | 516 | 479 | 481 | 468 | 451 | 439 | 418 | ||||||
| Inventory Net | 104 | 65 | 69 | 69 | 57 | 59 | 57 | 46 | 43 | 37 | 38 | 29 | ||||||
| Prepaid Expense Current | 217 | 225 | 171 | 178 | - | - | 49 | - | - | - | - | - | ||||||
| Other Assets Current | 39 | 63 | 116 | 68 | 121 | 119 | 64 | 122 | 120 | 101 | 98 | 108 | ||||||
| Assets Current | 1,638 | 2,436 | 2,523 | 2,158 | 1,749 | 1,638 | 1,725 | 1,877 | 1,670 | 1,799 | 1,607 | 1,650 | ||||||
| Inventory Noncurrent | 149 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 92 | 1,331 | 1,063 | 999 | 874 | 815 | 740 | 644 | 638 | 700 | 688 | 455 | ||||||
| Operating Lease Right Of Use Asset | 448 | 447 | 455 | 469 | 492 | 502 | 509 | 257 | 263 | 271 | 277 | 81 | ||||||
| Equity Securities Fv Ni Current And Noncurrent | 147 | 146 | 121 | 118 | 88 | 94 | 125 | 127 | 144 | 164 | 162 | 133 | ||||||
| Property Plant And Equipment Net | 91 | 91 | 90 | 97 | 92 | 87 | 83 | 80 | 80 | 75 | 71 | 69 | ||||||
| Intangible Assets Net Excluding Goodwill | 2,226 | - | - | 36 | 37 | 36 | 37 | 35 | 34 | 34 | 36 | 35 | ||||||
| Goodwill | 501 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Assets Net | 9 | 381 | 320 | 369 | 537 | 499 | 486 | 454 | 420 | 378 | 363 | 383 | ||||||
| Other Assets Noncurrent | 59 | 74 | 60 | 20 | 22 | 15 | 52 | 62 | 58 | 51 | 50 | 43 | ||||||
| Assets | 5,359 | 4,906 | 4,632 | 4,266 | 3,890 | 3,688 | 3,719 | 3,535 | 3,305 | 3,472 | 3,251 | 2,848 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 808 | 773 | 674 | 584 | 490 | 475 | 462 | 393 | 359 | 417 | 449 | 503 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 0 | 0 | 0 | 123 | 170 | 170 | ||||||
| Embedded Derivative Fair Value Of Embedded Derivative Liability | - | - | - | - | - | - | - | - | - | 136 | - | - | ||||||
| Other Liabilities Current | 66 | 59 | 69 | 54 | 57 | 48 | 46 | 37 | 40 | 37 | 36 | 19 | ||||||
| Liabilities Current | 875 | 832 | 743 | 638 | 546 | 523 | 508 | 430 | 399 | 713 | 655 | 692 | ||||||
| Deferred Income Tax Liabilities Net | 92 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 402 | 406 | 415 | 428 | 439 | 448 | 455 | 251 | 256 | 253 | 258 | 86 | ||||||
| Other Liabilities Noncurrent | 298 | 261 | 220 | 196 | 210 | 182 | 166 | 135 | 141 | 121 | 106 | 69 | ||||||
| Liabilities | 1,666 | 1,499 | 1,378 | 1,262 | 1,196 | 1,152 | 1,129 | 816 | 796 | 1,086 | 1,019 | 846 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,964 | 2,817 | 2,792 | 2,696 | 2,597 | 2,532 | 2,555 | 2,623 | 2,555 | 2,496 | 2,382 | 2,309 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 5 | 0 | 13 | 13 | 13 | 9 | 6 | 15 | 3 | 3 | 7 | -2 | ||||||
| Retained Earnings Accumulated Deficit | 724 | 590 | 448 | 294 | 85 | -5 | 29 | 81 | -49 | -114 | -157 | -305 | ||||||
| Stockholders Equity | 3,694 | 3,407 | 3,253 | 3,004 | 2,694 | 2,536 | 2,590 | 2,719 | 2,509 | 2,386 | 2,232 | 2,002 | ||||||
| Liabilities And Stockholders Equity | 5,359 | 4,906 | 4,632 | 4,266 | 3,890 | 3,688 | 3,719 | 3,535 | 3,305 | 3,472 | 3,251 | 2,848 | ||||||
| Debt Instrument Face Amount | - | - | - | - | - | - | - | - | - | 170 | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 220 | 220 | 220 | 220 | 220 | 220 | 220 | 220 | 220 | 220 | 220 | 220 | ||||||
| Common Stock Shares Issued | 102 | 101 | 100 | 100 | 99 | 99 | 99 | 101 | 101 | 101 | 99 | 98 | ||||||
| Shares Outstanding | 102 | 101 | 100 | 100 | 99 | 99 | 99 | 101 | 101 | 101 | 99 | 98 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNEUROCRINE BIOSCIENCES INC (NBIX) — SEC Financial Statements & Analysis
NEUROCRINE BIOSCIENCES INC (NBIX) is a biological products, (no diagnostic substances) company, incorporated in DE. NEUROCRINE BIOSCIENCES INC trades on Nasdaq as: NBIX. NEUROCRINE BIOSCIENCES INC (NBIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, NEUROCRINE BIOSCIENCES INC carries a market cap of $17.02B, a P/E ratio of 24.13x, a P/B ratio of 4.61x, a P/S ratio of 5.05x, an enterprise value of $16.68B, and an EV/EBITDA multiple of 20.26x. On profitability, it posts a gross margin of 97.97%, an operating margin of 23.56%, a net margin of 20.91%, a Return on Equity (ROE) of 22.09%, a Return on Assets (ROA) of 15.26%, and a Return on Invested Capital (ROIC) of 20.24%. Per share, it reports EPS of $6.99, diluted EPS of $6.77, free cash flow per share of $8.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 34.42% year-over-year, net income growth of 102.56% year-over-year, and EPS growth of 98.54% year-over-year. On the balance sheet, it maintains a current ratio of 1.87x, a quick ratio of 1.51x, working capital of $763.00M, a debt-to-equity ratio of 0.45x, a debt ratio of 0.31, an interest coverage ratio of 274.07x, free cash flow of $865.60M (TTM), and net debt of $-338.90M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.02B
- P/E TTM
- 24.13x
- EPS TTM
- $6.99
- P/B TTM
- 4.61x
- ROE TTM
- 22.09%
- ROA TTM
- 15.26%
- Debt To Equity
- 0.45x
- Free Cash Flow TTM
- $865.60M
- Net Revenue TTM Growth 1Y
- 34.42%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NEUROCRINE BIOSCIENCES INC in?
NEUROCRINE BIOSCIENCES INC (NBIX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does NBIX trade on?
NEUROCRINE BIOSCIENCES INC (NBIX) trades on the Nasdaq.
Where is NEUROCRINE BIOSCIENCES INC incorporated?
NEUROCRINE BIOSCIENCES INC is incorporated in DE.
When was NEUROCRINE BIOSCIENCES INC (NBIX)'s most recent SEC filing?
NEUROCRINE BIOSCIENCES INC (NBIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31.
What is NBIX's market cap?
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $17.02B as of 2026-06-30.
What is NBIX's P/E ratio?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month P/E ratio is 24.13x as of 2026-06-30.
What is NBIX's EPS (earnings per share)?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month EPS is $6.99 as of 2026-06-30.
What is NBIX's ROE (return on equity)?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month Return on Equity (ROE) is 22.09% as of 2026-06-30.
What is NBIX's ROA (return on assets)?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month Return on Assets (ROA) is 15.26% as of 2026-06-30.
What is NBIX's ROIC (return on invested capital)?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month Return on Invested Capital (ROIC) is 20.24% as of 2026-06-30.
What is NBIX's EV/EBITDA?
NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month EV/EBITDA is 20.26x as of 2026-06-30.